Pharsight

Oxlumo patents expiration

Can you believe OXLUMO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(4 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(5 years from now)

US11060093 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

US10465195 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

US9828606 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

US10487330 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(11 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(11 years from now)

US10612027 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(11 years from now)

US10478500 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
Oct, 2035

(11 years from now)

US11446380 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Oct, 2035

(11 years from now)

US11261447 ALNYLAM PHARMS INC Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Nov, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435692 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

Oxlumo is owned by Alnylam Pharms Inc.

Oxlumo contains Lumasiran Sodium.

Oxlumo has a total of 14 drug patents out of which 0 drug patents have expired.

Oxlumo was authorised for market use on 23 November, 2020.

Oxlumo is available in solution;subcutaneous dosage forms.

Oxlumo can be used as treatment of primary hyperoxaluria type 1 (ph1).

Drug patent challenges can be filed against Oxlumo from 23 November, 2024.

The generics of Oxlumo are possible to be released after 20 November, 2038.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-339) Nov 23, 2027
New Chemical Entity Exclusivity(NCE) Nov 23, 2025
Orphan Drug Exclusivity(ODE-415) Oct 06, 2029
New Indication(I-901) Oct 06, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LUMASIRAN SODIUM ingredient

NCE-1 date: 23 November, 2024

Market Authorisation Date: 23 November, 2020

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

OXLUMO family patents

Family Patents